buprenorphine / naloxone

Table of contents


On 30 April 2020, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Suboxone. The marketing authorisation holder for this medicinal product is Indivior Europe Limited.

The CHMP adopted a new pharmaceutical form (sublingual film) associated with four new strengths (2/0.5, 4/1, 8/2, and 16/4 mg) for either sublingual or buccal use. The new formulation adds additional safety features to prevent intravenous misuse.

For information, the full indications for Suboxone sublingual film will be as follows:

Substitution treatment for opioid drug dependence, within a framework of medical, social and psychological treatment. The intention of the naloxone component is to deter intravenous misuse. Suboxone is indicated in adults and adolescents over 15 years of age who have agreed to be treated for addiction.

Detailed recommendations for the use of this product will be described in the updated summary of product characteristics (SmPC), which will be published in the revised European public assessment report (EPAR), and will be available in all official European Union languages after a decision on this change to the marketing authorisation has been granted by the European Commission.

Key facts

Agency product number
International non-proprietary name (INN) or common name
  • buprenorphine / naloxone
Active substance
  • buprenorphine
  • naloxone
Therapeutic area
Opioid-Related Disorders
Date opinion adopted
Company name
Indivior Europe Limited
Application type

Related content

How useful was this page?

Add your rating
3 ratings